Bioequivalence study of two different coated tablet formulations of finasteride in healthy volunteers.
This study was conducted in order to assess the bioequivalence of two different coated tablet formulations containing 5 mg finasteride (CAS 98319-26-7). Twenty-six healthy volunteers were enrolled in an open, randomised, crossover single dose study with 2 periods x 2 sequences and a minimum washout period of 7 days. Plasma samples were obtained over 24 h (at baseline, +0.5 h, +1 h, +1.5 h, +2 h, +2.5 h, +3 h, 3.5 h, +4 h, +4.5 h, +5 h, +6 h, +8 h, +10 h, +12 h, +16 h and +24 h after administration). Finasteride levels were determined by high-pressure liquid chromatography with tandem mass detection, HPLC-MS/ MS, (LOQ 0.50 ng/mL). Pharmacokinetic parameters used for bioequivalence assessment (AUClast and Cmax were main evaluation criteria, however, AUCinf was also analysed) were determined from the finasteride concentration data using non-compartmental analysis. The 90 % confidence intervals (obtained by ANOVA) were 86.31-98.69 for Cmax, 95.40-104.88 for AUClast and 96.20-105.81 for AUCinf that is, they were all within the predefined ranges. It may be therefore concluded that the evaluated formulations are bioequivalent in terms of rate and extent of absorption.
Almeida
Ana
A
Medical Department, Grupo Tecnimede, Prior Velho (Portugal).
Almeida
Susana
S
Filipe
Augusto
A
Gagnon
Stéphanie
S
Mirapeix
Aitor
A
Girard
Benoît
B
Tanguay
Mario
M
D000293:Adolescent; D000328:Adult; D019540:Area Under Curve; D002138:Calibration; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D018120:Finasteride / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D006207:Half-Life; D006801:Humans; D008297:Male; D008875:Middle Aged; D013608:Tablets, Enteric-Coated; D013810:Therapeutic Equivalency
D004791:Enzyme Inhibitors; D013608:Tablets, Enteric-Coated; D018120:Finasteride